// App-Quantinova.ai

SAT0376 : DOES SUPPRESSION OF IL-4 AND IL-13 LEAD TO THE DEVELOPMENT OF NEW ONSET SPONDYLO-ARTHRITIS IN SUSCEPTIBLE PATIENTS?

Researchers

Presenter

  • C. Hughes

Principal Investigators

  • B. Menon

  • R. Woolf

  • Z. Willsmore

  • C. Smith

  • A. Pink

  • L. B. Kirkham

Medical Centers

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Guy’s and St Thomas’ NHS Foundation Trust, St John's Institute of Dermatology, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory Arthritis

Biomarkers

  • Interleukin 13

  • Interleukin 4

Drug/Treatment

  • Dupilumab

  • IL-4

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Eli Lilly and Company and Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved